loading
Schlusskurs vom Vortag:
$22.20
Offen:
$23.06
24-Stunden-Volumen:
28,959
Relative Volume:
0.31
Marktkapitalisierung:
$776.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.54%
1M Leistung:
-26.43%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$21.37
$23.79
1-Wochen-Bereich:
Value
$19.57
$25.04
52-Wochen-Spanne:
Value
$19.57
$31.13

Oruka Therapeutics Inc Stock (ORKA) Company Profile

Name
Firmenname
Oruka Therapeutics Inc
Name
Telefon
650-606-7910
Name
Adresse
855 OAK GROVE AVE., MENLO PARK
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
ORKA's Discussions on Twitter

Vergleichen Sie ORKA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ORKA 21.50 776.97M 0 0 0 0.00
VRTX 447.00 115.74B 10.63B -479.80M -1.35B 13.33
REGN 739.78 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.30 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.57 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.41 24.49B 3.30B -501.07M 1.03B 11.54

Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten

pulisher
Nov 19, 2024

Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference - The Manila Times

Nov 19, 2024
pulisher
Nov 19, 2024

Oruka Therapeutics to Present at Piper Sandler Healthcare Conference | Psoriasis Drug Developer | ORKA Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference - GlobeNewswire

Nov 19, 2024
pulisher
Nov 18, 2024

Oruka Therapeutics gains approval for preferred stock conversion - Investing.com

Nov 18, 2024
pulisher
Nov 16, 2024

Oruka Therapeutics adjusts financials post-merger By Investing.com - Investing.com Canada

Nov 16, 2024
pulisher
Nov 14, 2024

JANUS HENDERSON GROUP PLC Acquires New Stake in Oruka Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Oruka Therapeutics Raises $475M, Accelerates Clinical Timeline for Key Drug Programs | ORKA Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 04, 2024

Oruka Therapeutics to Present at Multiple November Investor Conferences - StockTitan

Nov 04, 2024
pulisher
Oct 11, 2024

Oruka stock draws buy rating at Stifel (NASDAQ:ORKA) - Seeking Alpha

Oct 11, 2024
pulisher
Oct 07, 2024

Oruka Therapeutics shares gain buy rating as H.C. Wainwright sees strong future in psoriasis treatment - Investing.com Canada

Oct 07, 2024
pulisher
Oct 04, 2024

Oruka Therapeutics Adjusts Executive Severance Agreements - TipRanks

Oct 04, 2024
pulisher
Sep 27, 2024

Oruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News Summary - Benzinga

Sep 27, 2024
pulisher
Sep 25, 2024

Oruka shares rise as TD Cowen maintains buy on drug potential - Investing.com Canada

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics reveals promising preclinical data for psoriasis treatment - Investing.com

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of ... - The Bakersfield Californian

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

Ordell Minerals Advances Gold Prospects with Phase 2 Drilling - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Orkla ASA (OTCMKTS:ORKLY) Sets New 1-Year High at $9.47 - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Orgenesis announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Orora (OTCMKTS:ORRYY) Shares Up 32.6% - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Why Orgenesis (ORGS) Stock Is Down 23% Today - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

‘Omni Loop’ takes a bit too much on its plate - Daily Trojan Online

Sep 23, 2024
pulisher
Sep 22, 2024

Private Auckland hospital doubles in size: New $3m robot, extra beds, surgical expansion - New Zealand Herald

Sep 22, 2024
pulisher
Sep 22, 2024

Organon: A Surprising Deal (NYSE:OGN) - Seeking Alpha

Sep 22, 2024
pulisher
Sep 21, 2024

‘Omni Loop’ (2024) Movie ReviewNothing New | MOVIESR.NET - Midgard Times

Sep 21, 2024
pulisher
Sep 21, 2024

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $41.25 Average PT from Analysts - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Sep 20, 2024
pulisher
Sep 19, 2024

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Leerink Partners - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Ocugen Inc [OCGN] Stock bought by Insider RAMESH KUMAR for $0.15 million - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

‘Omni Loop’ Review: Sci-Fi Indie Offers Some Ham-Fisted Heart - Observer

Sep 18, 2024
pulisher
Sep 18, 2024

Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Sep 18, 2024
pulisher
Sep 18, 2024

TD Cowen Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Leerink Partners starts drug developer Oruka with 'outperform' - XM

Sep 17, 2024
pulisher
Sep 17, 2024

Oruka Therapeutics initiated with an Outperform at Leerink - TipRanks

Sep 17, 2024
pulisher
Sep 16, 2024

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections - Benzinga

Sep 16, 2024
pulisher
Sep 16, 2024

Roche scores first, with FDA approval of Ocrevus Zunovo for MS - The Pharma Letter

Sep 16, 2024
pulisher
Sep 16, 2024

Analysts Issue Forecasts for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World

Sep 16, 2024
pulisher
Sep 16, 2024

FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology

Sep 16, 2024
pulisher
Sep 15, 2024

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group - Defense World

Sep 15, 2024
pulisher
Sep 13, 2024

Oruka Therapeutics Secures $200M to Advance Skin Disease Treatments - TipRanks

Sep 13, 2024
pulisher
Sep 13, 2024

FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia

Sep 13, 2024
pulisher
Sep 13, 2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire

Sep 13, 2024
pulisher
Sep 13, 2024

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - STAT

Sep 13, 2024
pulisher
Sep 13, 2024

Oruka to advance psoriasis programs into clinic next year - BioWorld Online

Sep 13, 2024
pulisher
Sep 12, 2024

Jefferies starts Oruka Therapeutics with buy, $40 target - Investing.com UK

Sep 12, 2024
pulisher
Sep 12, 2024

Biotech firm enters $200M agreement - The Business Journals

Sep 12, 2024
pulisher
Sep 12, 2024

Oruka Therapeutics secures $200 million in PIPE financing By Investing.com - Investing.com Canada

Sep 12, 2024

Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)

Es liegen keine Finanzdaten für Oruka Therapeutics Inc (ORKA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Oruka Therapeutics Inc-Aktie (ORKA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
JANUS HENDERSON GROUP PLC
10% Owner
Jul 24 '24
Buy
3.20
189,856
606,873
2,081,168
JANUS HENDERSON GROUP PLC
10% Owner
Jul 25 '24
Buy
3.05
30,227
92,292
2,111,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 03 '24
Buy
3.55
166,042
589,565
1,648,577
JANUS HENDERSON GROUP PLC
10% Owner
Jul 11 '24
Buy
3.45
94,537
326,304
1,891,312
JANUS HENDERSON GROUP PLC
10% Owner
Jul 10 '24
Buy
3.46
55,463
192,130
1,796,775
JANUS HENDERSON GROUP PLC
10% Owner
Jul 08 '24
Buy
3.46
47,492
164,190
1,724,395
JANUS HENDERSON GROUP PLC
10% Owner
Jul 05 '24
Buy
3.43
28,326
97,065
1,676,903
JANUS HENDERSON GROUP PLC
10% Owner
Jul 09 '24
Buy
3.43
16,917
58,091
1,741,312
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):